Supreme Court asked to pause ruling blocking telehealth and mail access to abortion pills
Danco Laboratories has asked the Supreme Court to pause a lower court ruling that requires mifepristone, an abortion pill, to be dispensed in person nationwide. The company argues the ruling disrupts long-standing FDA-approved distribution methods and causes irreparable economic harm. The decision stems from a Fifth Circuit Court ruling favoring Louisiana's challenge to telehealth and mail delivery of the medication.
- ▪The Fifth Circuit Court of Appeals ruled that mifepristone must be dispensed in person, blocking telehealth and mail access.
- ▪Danco Laboratories, the maker of Mifeprex, filed an emergency appeal asking the Supreme Court to pause the ruling.
- ▪The FDA had allowed mail and telehealth distribution of mifepristone since 2023, building on a temporary policy from the Covid-19 pandemic.
- ▪Planned Parenthood supported Danco’s appeal, calling the lower court’s decision harmful to patient access.
- ▪Medication abortions account for more than half of all abortions in the United States.
Opening excerpt (first ~120 words) tap to expand
Politics NewsSupreme Court asked to pause ruling blocking telehealth and mail access to abortion pillsThe emergency appeal comes a day after a federal appeals court granted Louisiana's request to require that mifepristone be dispensed in person.Listen to this article with a free account00:0000:00In its filing, Danco Laboratories argued that the lower court went too far by immediately limiting the sale of mifepristone to in-person distributionAmanda Andrade-Rhoades / AP fileShareAdd NBC News to GoogleMay 2, 2026, 3:51 PM EDTBy Alexandra MarquezDanco Laboratories, one of the makers of the abortion pill mifepristone, asked the Supreme Court on Saturday to block a lower court ruling that imposed a nationwide requirement for the medication to be dispensed in person.Subscribe to read this story…
Excerpt limited to ~120 words for fair-use compliance. The full article is at NBC News Top Stories.
Discussion
0 commentsMore from NBC News Top Stories
